European Medicines Agency (EMA) organized a workshop on supporting innovation in cardiovascular medicines and medical devices in the EU. The workshop was on 1-2 July 2026.
Cardiovascular diseases CVD account for a high burden in morbidity and mortality rates in European union. There are required actions to leverage the current opportunities to suport research, innovation and personalised approach to adress the gaps in current avialable therapeutic options for patients.
This multi-stakeholder workshop covered interdisciplinary discussions
addressing a range of important topics including clinical gaps, development challenges and regulatory strategies, advancing prevention and treatment in cardiovascular (CV) diseases and their overlapping areas including diabetes, obesity, lipid lowering and renal aspects. The role of real-world data as well as digitalisation and AI in CV innovation was widely discussed. The participants were: patients, patients organizations, healthcare professionals, academia,
regulators, and industry. I represented WPA on this workshop what gave me a good insight in Health Plan, extended my knowledge about AI in CV innovation.
The overall objective of the workshop was to enhance understanding among stakeholders on the interplay of regulation and innovation in CV medicines and medical devices.
Participants stressed strong link between diabetes, cardiovascular, kidney and liver diseases which is necessery to develop holistic, patient centred prevention and treatment.
Key innovation priorities include use of health data, digitalization, research, healthcare for underserved populations.
